﻿<?xml version="1.0" encoding="UTF-8"?>
<records>
  <record>
    <language>eng</language>
    <publisher>Science and Education Publishing</publisher>
    <journalTitle>International Journal of Celiac Disease</journalTitle>
    <eissn>2334-3486</eissn>
    <publicationDate>2017-08-08</publicationDate>
    <volume>5</volume>
    <issue>3</issue>
    <startPage>95</startPage>
    <endPage>96</endPage>
    <doi>10.12691/ijcd-5-3-6</doi>
    <publisherRecordId>IJCD2017536</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Deamidated Gliadin Peptide Antibodies; is the Time to Use as a Routine Test for Celiac Disease</title>
    <authors>
      <author>
        <name>Mohammad Rostami Nejad</name>
        <email>m.rostamii@gmail.com</email>
        <affiliationId>1</affiliationId>
      </author>
    </authors>
    <affiliationsList>
      <affiliationName affiliationId="1">Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliationName>
    </affiliationsList>
    <abstract language="eng">Antibodies to deamidated gliadin peptides (DGP-AGA) have newly been presented into the extensive variety of serologic examinations for celiac disease (CD). In compare with the modern AGA, DGP-AGA indicated a higher sensitivity and specificity for CD and simply identified by ELISA kits. Nevertheless, even though the very favorable outcomes, DGP-AGA are not yet regularly used in the serologic checkup for CD. An antibody approach could initiate development in the diagnostic precision of serology for CD screening.</abstract>
    <fullTextUrl format="pdf">http://pubs.sciepub.com/ijcd/5/3/6/ijcd-5-3-6.pdf</fullTextUrl>
    <keywords language="eng">
      <keyword>
        <b>
        </b>deamidated gliadin peptides</keyword>
      <keyword>celiac disease</keyword>
      <keyword>serologic checkup</keyword>
    </keywords>
  </record>
</records>